A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Severe SepsisSeptic Shock
Interventions
DRUG

AZD9773

A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days

DRUG

Placebo

Placebo

Trial Locations (52)

Unknown

Research Site, Blacktown

Research Site, Wollongong

Research Site, Herston

Research Site, Nambour

Research Site, Woollongabba

Research Site, Adelaide

Research Site, Clayton

Research Site, Footscray

Research Site, Fremantle

Research Site, Antwerp

Research Site, Brussels

Research Site, Genk

Research Site, Godinne

Research Site, Liège

Research Site, Ottignies

Research Site, Edmonton

Research Site, Vancouver

Research Site, Victoria

Research Site, Winnipeg

Research Site, Halifax

Research Site, Ottawa

Research Site, Windsor

Research Site, Québec

Research Site, Hradec Králové

Research Site, Prague

Research Site, Ústí nad Labem

Research Site, Kuopio

Research Site, Tampere

Research Site, Angers

Research Site, Dijon

Research Site, La Roche-sur-Yon

Research Site, Limoges

Research Site, Montauban

Research Site, Nantes

Research Site, Nîmes

Research Site, Orléans

Research Site, Paris

Research Site, Poitiers

Research Site, Saint-Michel

Research Site, Toulon

Research Site, Toulouse

Research Site, Tours

Research Site, Vandœuvre-lès-Nancy

Research Site, Palma de Mallorca

Research Site, Sabadell

Research Site, Barcelona

Research Site, Terrassa

Research Site, Santiago de Compostela

Research Site, Getafe

Research Site, Madrid

Research Site, Oviedo

Research Site, Valencia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY